Severe eczema in Wiskott–Aldrich syndrome‐related disorder successfully treated with dupilumab

Severe eczema in Wiskott–Aldrich syndrome‐related disorder successfully treated with dupilumab

Treatment of severe eczema in patients with primary immunodeficiencies can be particularly challenging as there are no guidelines with regards to these conditions. Dupilumab is an interleukin (IL)‐4Rα antagonist that inhibits both IL‐4 and IL‐13 and is approved for the treatment of atopic dermatitis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric dermatology 2024-01, Vol.41 (1), p.143-144
Hauptverfasser: Alzahrani, Fatmah, Miller, Holly K., Sacco, Keith, Dupuy, Elizabeth
Format: Artikel
Sprache:eng
Schlagworte:
Atopic dermatitis
dermatitis‐eczemas NOS
Dermatology
Eczema
immunodeficiency
Monoclonal antibodies
Patients
Pediatrics
Primary immunodeficiencies
therapysystemic
Wiskott-Aldrich syndrome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Treatment of severe eczema in patients with primary immunodeficiencies can be particularly challenging as there are no guidelines with regards to these conditions. Dupilumab is an interleukin (IL)‐4Rα antagonist that inhibits both IL‐4 and IL‐13 and is approved for the treatment of atopic dermatitis in pediatric patients. In this report, we describe a patient with a case of severe eczema in the context of Wiskott–Aldrich syndrome‐related disorder, who was successfully treated with dupilumab.
ISSN:0736-8046
1525-1470
DOI:10.1111/pde.15397